A 71-year-old man with a history of permanent atrial fibrillation is maintained on a novel… — USMLE Step 3

A 71-year-old man with a history of permanent atrial fibrillation is maintained on a novel oral anticoagulant (NOAC) at a standard daily dose to prevent thromboembolism. The NOAC has a baseline oral bioavailability ( $F$ ) of $30\%$ , is a known substrate of intestinal P-glycoprotein (P-gp) efflux pumps, and undergoes extensive hepatic elimination via the cytochrome P450 3A4 (CYP3A4) pathway. The baseline elimination half-life ( $t_{1/2}$ ) of this medication is 10 hours.

The patient is recently diagnosed with a systemic fungal infection and is started on oral itraconazole, a potent dual inhibitor of both P-gp and CYP3A4. Co-administration of itraconazole increases the NOAC's oral bioavailability to $90\%$ and reduces its hepatic clearance ( $CL$ ) by $50\%$ .

One week later, the patient presents to the emergency department with severe gastrointestinal hemorrhage and requires urgent resuscitation. Assuming the volume of distribution ( $V_d$ ) remains constant, which of the following accurately describes the pharmacokinetic alterations responsible for this patient's presentation?

The steady-state systemic exposure (AUC) increases 6-fold due to synergistic changes in absorption and clearance, and the elimination half-life prolongs to 20 hours.Answer
B
The steady-state systemic exposure (AUC) increases 3-fold driven exclusively by enhanced intestinal absorption, while the elimination half-life remains constant at 10 hours.
C
The steady-state systemic exposure (AUC) increases 2-fold primarily due to reduced hepatic elimination, and the elimination half-life prolongs to 20 hours.
D
The steady-state systemic exposure (AUC) increases 1.5-fold due to competing pharmacokinetic alterations, and the elimination half-life is reduced to 5 hours.
E
The elimination half-life prolongs to 20 hours leading to a 2-fold increase in systemic exposure (AUC), as changes in oral bioavailability do not affect steady-state concentrations for continuous daily dosing.

Answer

The steady-state systemic exposure (AUC) increases 6-fold due to synergistic changes in absorption and clearance, and the elimination half-life prolongs to 20 hours.

The correct answer accurately synthesizes two distinct pharmacokinetic equations. First, the steady-state systemic exposure (or AUC) of an orally administered drug is determined by the equation

\text{AUC} = \frac{F \times \text{Dose}}{CL}

. The administration of itraconazole increases bioavailability (

F

) from

30\%

90\%

(a 3-fold multiplier) and decreases clearance (

CL

) by

50\%

0.5

multiplier). The combined mathematical effect on AUC is

3 / 0.5 = 6

. Therefore, the total systemic exposure increases 6-fold, explaining the severe hemorrhage. Second, the elimination half-life is determined by the equation

t_{1/2} = \frac{0.693 \times V_d}{CL}

. Because clearance is reduced by

50\%

and the volume of distribution (

V_d

) is unchanged, the half-life exactly doubles from 10 hours to 20 hours.

Step-by-Step Solution

Calculate the fold-change in oral bioavailability (F).

F increases from 30% to 90%, which is a 3-fold increase.

Itraconazole inhibits intestinal P-gp, significantly decreasing the efflux of the drug back into the gut lumen and increasing the fraction absorbed.

Calculate the fold-change in clearance (CL).

CL is reduced by 50%, meaning the new CL is 0.5 times the original CL.

Itraconazole inhibits hepatic CYP3A4, thereby reducing the liver's ability to metabolize the drug.

Determine the new steady-state systemic exposure (AUC).

AUC increases 6-fold.

Steady-state AUC is directly proportional to F and inversely proportional to CL (AUC = F × Dose / CL). The combined effect is (3 × F) / (0.5 × CL) = 6-fold increase in AUC.

Determine the new elimination half-life (t1/2).

The half-life increases from 10 hours to 20 hours.

Half-life is inversely proportional to clearance (t1/2 = 0.693 × Vd / CL). Since Vd is constant and CL is halved (0.5), the half-life doubles.

Key Concept

Pharmacokinetic impact of dual P-gp and CYP450 inhibition on bioavailability, clearance, steady-state AUC, and half-life.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic